21:27 , Jun 27, 2019 |  BC Extra  |  Company News

Conserving cash, ImmunoGen to pursue narrower indication for bruised mirvetuximab

Immunogen is gutting its workforce and shelving at least two early stage programs to focus on the asset that put the biotech in this precarious position in the first place, antibody-drug conjugate mirvetuximab soravtansine. ImmunoGen...
14:19 , May 14, 2019 |  BC Innovations  |  Distillery Techniques

A circulating tumor cell capture device for cancer diagnosis

TECHNIQUES CATEGORY: Assays and screens TECHNOLOGY: Diagnostic assays An chip-based device for capturing circulating tumor cells (CTCs) could enable more accurate diagnosis of cancer than single-draw liquid biopsies. The device uses a pump and catheters...
19:05 , May 2, 2019 |  BC Innovations  |  Translation in Brief

Continuously capturing cancer cells

A wearable device that captures and isolates circulating tumor cells over the course of a few hours could offer better diagnostic accuracy than single-draw liquid biopsies that screen smaller amounts of blood. A University of...
21:48 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Merrimack's bispecific mAb against c-MET and EpCAM for solid tumors

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer; gastric cancer; lung cancer Cell culture and mouse studies identified a bispecific mAb against c-MET and EpCAM that could help treat colorectal, lung and gastric cancers. In human colorectal...
20:27 , Mar 19, 2019 |  BC Extra  |  Preclinical News

Merrimack develops bispecific against c-MET oncogene

Merrimack has overcome hurdles to antibody targeting of c-MET with a bispecific that increases avidity by anchoring to a tumor surface protein. Marketed small molecules inhibiting c-MET, which drives tumor formation, metastasis and resistance to...
21:28 , Aug 20, 2018 |  BC Extra  |  Preclinical News

Malaria protein helps detect circulating tumor cells

VarCT Diagnostics ApS is developing a cancer diagnostic that employs a malaria protein to target circulating tumor cells based on research from University of Copenhagen and colleagues. The academic team previously showed that the recombinant...
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
18:22 , May 25, 2018 |  BC Week In Review  |  Clinical News

Sesen reports Phase III data for bladder cancer candidate Vicinium

Sesen Bio Inc. (NASDAQ:SESN) (formerly Eleven Biotherapeutics Inc.) said Vicinium (VB4-845) led to a complete response rate of 42% at three months in 77 evaluable bladder cancer patients with carcinoma in situ (CIS) in the...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
20:11 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends continuation of Phase III Vicinium trial in NMIBC

Eleven Biotherapeutics Inc. (NASDAQ:EBIO) said an independent DSMB recommended continuation of its Phase III trial evaluating Vicinium (VB4-845) via intravesical instillation to treat high-grade non-muscle invasive bladder cancer (NMIBC) patients who previously failed treatment with...